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Abstract
Only a small proportion of pharmaceuticals available for commercial use have been monitored in the aquatic environment, and
even less is known about the effects on organisms.With thousands of pharmaceuticals in use, it is not feasible tomonitor or assess
the effects of all of these compounds. Prioritisation schemes allow the ranking of pharmaceuticals based on their potential as
environmental contaminants, allowing resources to be appropriately used on those which are most likely to enter the environment
and cause greatest harm. Many different types of prioritisation schemes exist in the literature and those utilising predicted
environmental concentrations (PECs), the fish plasma model (FPM), critical environmental concentrations (CECs) and acute
ecotoxicological data were assessed in the current study using the 50 most prescribed drugs in the UK. PECs were found to be
overestimates of mean measured environmental concentrations but mainly underestimations of maximum concentrations. Acute
ecological data identified different compounds of concern to the other effects assessments although the FPM and CECs methods
were more conservative. These schemes highlighted antidepressants, lipid regulators, antibiotics, antihypertensive compounds
and ibuprofen as priority compounds for further study and regulation.
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Introduction
Concern over the presence of pharmaceuticals in the environ-
ment and the subsequent development of environmental risk
assessments (ERAs) for these compounds began in the 1990s
(Küster and Adler 2014). Currently, only Europe and the USA
have specific ERA protocols for the assessment of pharma-
ceuticals, which are required to be completed in order to reg-
ister them for commercial use (Adler et al. 2008). In 2006, an
EU regulation on the registration, evaluation, authorisation
and restriction of chemicals (REACH) came into effect, and
now all chemicals being manufactured in or imported to the
EU must be assessed following ECHA guidelines, including
information on potential risks and hazards to the environment.
However, prior to the implementation of such legislation,
pharmaceuticals have been released into the environment un-
regulated for years. The number of human pharmaceuticals in
use has been reported as being between 1500 and 10,000 (Guo
et al. 2016; Dong et al. 2013). Only a little over 200 of these
have been monitored in freshwaters and fewer in marine wa-
ters, and even less is known about their impacts once they
enter the aquatic environment (Fabbri and Franzellitti 2016;
Hughes et al. 2013). This has left continuing uncertainty sur-
rounding the environmental impacts of pharmaceuticals in the
aquatic environment. The use of a prioritisation scheme can
help address this by identifying a smaller set of compounds
which have the potential to enter the environment and pose a
biological risk. This can allow researchers and policy makers
to direct resources towards further study; they can help decide
which compounds need to be monitored in the environment
and which require more information on their fate and biolog-
ical effects (Mansour et al. 2016).
Many prioritisation schemes are based on existing ERAs,
which include the calculation of predicted environmental con-
centrations (PECs) and an assessment of the risk to biota.
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PECs are usually derived from usage data on the volume of
drugs produced per year, or number of prescriptions filed,
which may be further refined based on processes which affect
the compounds between production and entering the environ-
ment, such as metabolism, wastewater treatment and dilution
(Besse and Garric 2008). Often, where experimental data is
missing or chemical properties are not known, simplified
PECs, where little or no fate criteria are applied, may be cal-
culated to facilitate quick assessment of a large number of
chemicals (Ashton et al. 2004; Besse and Garric 2008;
Kostich and Lazorchak 2008). As a result, the PECs calculat-
ed in such schemes give broad predictions for a country or
large area and are not refined enough to give predictions at
different spatial or temporal scales.
PECs are usually paired with assessments of hazards to
biological organisms inhabiting the receiving environments.
One such method is through the use of risk quotients, which
determine if the predicted no effect concentrations (PNECs) of
a compound exceed PECs. If the result is greater than 1 then
the study compound is deemed to pose a threat (Hoyett et al.
2016). PNECs are usually calculated by selecting the most
sensitive LC50 and applying an assessment factor (Backhaus
and Faust 2012). Such experimental data is often unavailable
in the literature, however, and it is time consuming to generate
such data for a prioritisation scheme. Ecotoxicological
structure-activity relationships (ECOSAR) can be used to cal-
culate chronic and acute LC50 values and are allowed under
REACH guidelines (Sanderson et al. 2004; Ortiz de García
et al. 2013).
Pharmaceuticals are unique contaminants as they are de-
signed to be biologically active and, unlike many other envi-
ronmental contaminants, information from the medical litera-
ture on the pathways and effects of pharmaceuticals in verte-
brates is abundant. This information has been utilised to pro-
duce alternative methods of assessing the hazard of pharma-
ceuticals to biota. Fish are not biochemically different from
vertebrates and share many of the same drug targets (Huggett
et al. 2003). The fish plasma model utilises this information
and compares the human therapeutic concentration to a calcu-
lated fish plasma concentration. Vertebrates are usually more
sensitive to chemicals than invertebrates, due to shared targets.
It is thought that this model is a scheme sufficient to predict
the environmental hazard of chemicals (LaLone et al. 2014).
Despite their extensive development, the prioritisation
schemes which exist in the literature are varied and often
highlight different compounds of concern (Besse and Garric
2008; Donnachie et al. 2016; Roos et al. 2012). Moreover, it
can be difficult to compare them as they are applied to differ-
ent data sets and scenarios which can make it hard to under-
stand which compounds really are of most concern or to select
a scheme for use in research and management. The aim of this
paper was, therefore, to use a range of common prioritisation
schemes to assess the environmental risk of the 50 most
prescribed pharmaceuticals in the UK, highlight compounds





Information on the quantity of pharmaceuticals prescribed
was obtained from data released monthly by the National
Health Service England for 2014 (NHS 2014). The 50 most
prescribed compounds during this period were used for this
assessment. For each compound, the monthly and annual
mass of prescriptions was calculated (supplementary
material S1).
PECAwas calculated using (Eq. 1), where A is the amount
of pharmaceuticals dispensed (kg year−1), E is the fraction of
the compound excreted unchanged, V is the volume of waste
water per capita per day (assumed to be 200 l), P is the pop-
ulation of England in 2014, and D is the dilution of waste
water (assumed to be 10 times; EMEA 2006). This method
was derived from the approach detailed in the EU technical
guidance for risk assessment of human pharmaceuticals (EU
2003). Excretion rates were obtained from peer-reviewed lit-
erature or online databases and the highest excretion rate was
used in the calculation (supplementary material S2). PECB
further refined this equation by applying the removal rate for
pharmaceuticals in WWTPs (Eq. 2), where R is the removal
rate. Removal rates were obtained from peer-reviewed litera-
ture and where multiple removal rates were published for the
same compound, the lowest was chosen in order to create a
more conservative estimate (supplementary material S2). If no
removal rate, or a negative one, was found then it was as-
sumed to be 0. PECC included further refinement, taking into
account metabolism and removal in wastewater (Eq. 3).
PECA ¼ A EV P D 365 ð1Þ
PECB ¼ A 1−Rð ÞV P D 365 ð2Þ
PECC ¼ A E 1−Rð ÞV P D 365 ð3Þ
PECD (Eq. 4) is derived from the EMEA guidelines and
does not require prescription data to be calculated. Instead, it
includes the proportion of the population being treated with a
particular drug (Fpen), where a suggested value of 1% is used
(EMEA 2006). Dose is the maximum dosage per person and
Capstp is the capacity of the local WWTP (assumed to be
10,000; EMEA 2006). The EMEA guidelines also suggest
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the inclusion of information on the fraction of the compound
absorbed to suspended matter. Due to the unavailability of this
data for most compounds, this was not included (Besse et al.
2008).
PECD ¼ Elocalwater  1−Rð ÞV D Capstp
ð4Þ
Elocalwater ¼ Dose E Fpen Capstp ð5Þ
Each compound was ranked by each of the PEC calcula-
tions (supplementary material S3) and the mass prescribed
annually in order to compare how the different schemes al-
tered the predicted relative environmental risk.
Comparison with environmental concentrations
In order to compare the PECs to measured environmental
concentrations (MECs), data were taken from monitoring
studies carried out in the UK (Baker and Kasprzyk-Hordern
2013; Bound and Voulvoulis 2006; Burns et al. 2017; Burns
et al. 2018a; Kasprzyk-Hordern et al. 2008; Kasprzyk-
Hordern et al. 2009; Kay et al. 2016; Nakada et al. 2017;
Roberts and Thomas 2006; Ashton et al. 2004). Only moni-
toring studies from surface water were included, measure-
ments from influent and effluent were omitted. The mean
MEC across all studies was calculated and compared to each
of the PECs along with the maximum MEC.
Effect data
Fish plasma model
The FPM was calculated according to Huggett et al. (2003).
This model compares the human therapeutic plasma concen-
tration (HTPC) and the fish steady state concentration (FssPC)
to give an effective ratio (ER), a measure of risk (Eq. 6). FssPC
was estimated for each of the PEC values calculated in
BCalculations^ section (Eq. 7) and the HTPC was obtained
by using the peak serum concentration that is reached in
humans after the drug has been administered (cmax). Where
multiple cmax values were found, the higher value was used




FSSPC ¼ PEC x PBlood:Water ð7Þ
logPBlood:Water ¼ 0:73 logkow ð8Þ
The compounds were ranked from lowest to highest by ER.
Huggett et al. (2003) suggested that compounds with an ER <
1000 may warrant further assessment.
Critical environmental concentrations
Critical environmental concentrations (CECs) were proposed
by Fick et al. (2010) and utilise the concept of the FPM but are
independent of environmental concentrations. CECs are cal-





Information on the acute toxicity of each of the compounds
was obtained from reviews containing comprehensive exper-
imental ecotoxicological data or studies containing such data
provided by pharmaceutical companies (Sanderson and
Thomsen 2009; Sangion and Gramatica 2016a; Vestel et al.
2016). For compounds not included in these studies, LC50
values were obtained from risk assessments or scientific liter-
ature (supplementary material S4). Values were only included
if they followed standard protocols (for example, OECD, US
EPA), used at least five concentrations in the exposures and at
least three replicates per treatment. This data was unavailable
for 12 compounds, so ECOSAR (v 1.11) was used to estimate
LC50 values although the model was unable to estimate these
for 7 of the compounds. A relative ranking, where the ranking
was divided by the number of compounds in the scheme, was
used in order to compare rankings across all effect schemes.
Risk quotients (RQ) were calculated by dividing the lowest
LC50 value for fish, algae or daphnia by each of the PECs
calculated in BCalculations^ section. An assessment factor of
1000 was applied in order to account for any uncertainties and
provide a more conservative assessment. Those compounds
with a RQ > 1 deemed to be hazardous to the environment.
Results
Exposure criteria
Comparison of predicted environmental concentrations
between schemes
Metformin, gabapentin, flucloxacillin, amoxicillin, naproxen
and ibuprofen were ranked in the top 10 across all PEC
schemes, whereas tamsulosin, ethinylestradiol, fluticasone,
budesonide, beclomethasone, felodipine and tiotropium were
ranked in the bottom 10 (Fig. 1). These compounds were in
the top 10 and bottom 10 respectively when ranked by the
amount dispensed annually. For most compounds, there was
less than a 10 place difference between schemes
(supplementary material S3). Where larger differences
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occurred, it can mostly be attributed to different results be-
tween schemes which utilised usage data (PECA, PECB and
PECC) and PECD which did not. However, the PEC values for
individual compounds did differ greatly depending on which
scheme was used.
Comparison with measured environmental concentrations
MECs in the UK were available for 24 out of the 50 study
compounds. Of these, warfarin sodium, sertraline predniso-
lone and fluticasone propionate were below the limit of detec-
tion (LOD) in all studies. All of the schemes underestimated
the maximum concentrations for tramadol, salbutamol, para-
cetamol, ibuprofen and ethinylestradiol (Fig. 2). Maximum
MECs were overestimated for amoxicillin, diltiazem,
gabapentin and naproxen by all schemes. For the other com-
pounds, PECB overestimated maximum concentrations more
than the other schemes.
All PECs were overestimates of mean MECs for all of the
compounds, with the exception of ethinylestradiol and
salbutamol (Fig. 3). PECA, PECC and PECD also
underestimated the MECs of propranolol and tramadol.
Further to this, PECC and PECD underestimated the MECs
for paracetamol and codeine, respectively. The ratio for mean
MECs was much higher than those for maximum MECs for
all compounds. PECD overestimated MECs to a greater
degree than the other schemes, and PECC more accurately
predicted the mean MECs than the other schemes.
Effect criteria
For many of the compounds, LC50 values resulted in the
opposite ranking to the other schemes (supplementary
material S5). The FPM model, LOGKOW and CEC
schemes resu l ted in s imvas ta t in , a torvas ta t in ,
candesartan, ibuprofen and losartan being ranked in the
top 25%; however, the LC50 ranked these compounds as
lower priority (Fig. 4). The opposite was true for allopu-
rinol, alendronic acid, beclomethasone and amoxicillin.
Pregabalin, gabapentin, isosorbide mononitrate and
tiotropium were ranked in the bottom 25% across all
schemes. CECs highlighted some compounds as priority
that the other schemes did not; ethinylestradiol,
fluticasone propionate and beclomethasone diproprionate
had a higher relative ranking before the inclusion of PEC
values. As a compound class, antidepressants and antibi-
otics were given a high priority ranking, whereas bron-
chodilators and mucosal protectants did not.
All compounds had an ER ratio < 1000, with the excep-
tion of tiotropium and alendronic acid, where the ER
exceeded this value with all PECs (supplementary material
S6). Isosorbide mononitrate also had an ER < 1000 for
FPMA, and FPMC. Less compounds exceeded the RQ value
of 1; all PECs resulted in an RQ > 1 for amoxicillin
Fig. 2 Ratio of PEC: maximum
MEC for each of the schemes.
The line denotes a ratio of one
Fig. 1 Comparison of ranking of pharmaceuticals by compound class
between predicted environmental concentration schemes
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(supplementary material S6). PECB resulted in the RQ be-
ing exceeded for the allopurinol and fluoxetine and PECD
for allopurinol, fluoxetine and flucloxacillin.
Discussion
Comparison of schemes for predicted environmental
concentrations
For many of the compounds in this assessment, the ranking
within each PEC scheme was correlated with the amount dis-
pensed, which has also been found in other prioritisation stud-
ies (Ashton et al. 2004; Roos et al. 2012). Of the compounds
which were ranked in the top 10 across all schemes, metfor-
min, amoxicillin, naproxen and ibuprofen have previously
occurred on many priority lists (Burns et al. 2018b).
Gabapentin and flucloxacillin have only been listed of con-
cern in one prioritisation exercise each (Helwig et al. 2013;
Ortiz de García et al. 2013) and, as a result, monitoring studies
including these compounds are much lower. PECD results
were less closely related with the amount of compound dis-
pensed, as this was not included in the calculation. Instead,
PECD used the maximum dosage and assumed 1% of the
population was taking the compound. It is unsurprising that
compounds which have a higher dosage are also prescribed at
higher masses. However, for many compounds, the usage has
been found to surpass 1% (Pereira et al. 2017). As a result, the
inclusion of usage data in risk assessments is very important
and, where this is not available (e.g. many developing coun-
tries), its production should be seen as a high priority by gov-
ernments. As over the counter (OTC) sales of some products
have been attributed to up to 50% of this, it is very important
that these figures are available for risk assessment purposes
(Guo et al. 2016). Of the compounds assessed in the current
study, paracetamol, ibuprofen, diclofenac, omeprazole and
naproxen are available OTC in the UK. Even though OTC
data were not available, omeprazole was ranked between 10
and 20 across all schemes, and if OTC sales were also includ-
ed, it could bemuchmore important in terms of environmental
impact. Furthermore, many pharmaceuticals are also used for
veterinary purposes and these data are needed for more accu-
rate PEC production.
Although, for the majority of compounds, ranking by the
amount of pharmaceutical dispensed may be sufficient to es-
timate relative environmental exposure, some compounds un-
dergo extensive metabolism or removal in WWTPs, making
some refinement necessary. Amoxicillin, metformin,
gabapentin, ibuprofen and naproxen are prescribed in such
high numbers that the application of removal and excretion
data has little impact on their relative ranking. Gliclazide, on
the other hand, had a 20 place ranking difference between the
amount dispensed and PECA due to its extensive metabolism.
Those which were ranked between 20 and 40 showed more
variability in their ranking between schemes than those at the
top and bottom end, as they were dispensed in similar amount
Fig. 3 Ratios of PEC: meanMEC
for each of the schemes. The line
denotes a ratio of one
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to other compounds. Information on the metabolism of phar-
maceuticals was available in the scientific literature and phar-
maceutical databases, with little variation in reported values.
Removal rates during wastewater treatment had less of an
effect on the ranking of compounds than excretion rate. It is
possible that this is the result of the overall lack of information
of this process or variability within the data, depending on
external factors such as temperature and WWTP efficiency
(Golovko et al. 2014). For example, removal of metformin
has been reported to be as low as 0% and as high as 99%
(Santos et al. 2013). Variability such as this can have a great
impact on the ranking of compounds; PECB included the low-
er rate of removal of 0% which resulted in a ranking of 1;
however, using the higher removal rate of 99% would have
resulted in the lower ranking of 23. Furthermore, in some
cases, an increase in the compound concentration has been
seen in effluent as the result of conversion back to the parent
compound in WWTPs and so a negative removal rate would
have to be used in a PEC scheme to accurately take this oc-
currence into account (Paíga et al. 2016).
Comparison of predicted environmental
concentrations with measured environmental
concentrations
In the majority of cases, the PECs failed to accurately repre-
sent the MECs; mean MECs were mostly overestimated, and
half of the maximum MECs were underestimated by all
schemes. PECA, PECB and PECC were most accurate in esti-
mating mean MECs, despite overestimations. Nevertheless,
these afford a degree of environmental safety. When
interpreting these results, the lack of available monitoring data
needs to be taken into consideration and many compounds
were only measured at one time point and at one or two sites.
Concentrations of some pharmaceuticals have been shown to
fluctuate depending on seasonal and environmental condi-
tions, so more thorough monitoring studies are needed to fur-
ther validate methods for producing PECs (Moreno-González
et al. 2015). Ferrari et al. (2004) compared PECB and the
highest MECs for five pharmaceuticals in wastewater effluent
and rivers in France and Germany. In German effluents, these
concentrations were accurately predicted for carbamazepine
and diclofenac, but were underestimated (although by less
than a factor of 10) for propranolol, clofibric acid and
sulfamethoxazole, and overestimated for oflaxin. However,
in French effluents, MECs were overestimated for all
compounds showing that the scenario being assessed is
important when choosing a PEC model and that local factors
which could affect concentrations are considered. Burns et al.
(2017) also comparedMECs and PECs which were calculated
using local hydrological information alongside lowest remov-
al and highest excretion rates. MECs were accurately predict-
ed in one river but not another, which was attributed to
missing inputs. The inclusion of local hydrological informa-
tion such as this may help to produce more accurate PECs.
Comparison of effect-based methods
FPM, LogKOW and CEC schemes resulted in different rank-
ings to acute LC50 and triggered different compounds for fur-
ther assessment, which is concurrent with other recent studies,
showing that LogKOW has a strong influence on these calcu-
lations (Roos et al. 2012). Additionally, FPMs were more
conservative than RQs, triggering more compounds for fur-
ther assessment. Thus, simply ranking compounds by logKOW
could be a useful approach for determining the relative hazard
pharmaceuticals pose to biota. Nevertheless, although logKOW
is used in FPM and CEC models, it does not necessarily indi-
cate the compound will be toxic, but instead that it is likely to
be taken up by fish at a level sufficient to have a biological
effect (Schrieber et al. 2011). Instead, it is suggested that those
with an ER less than 1000 warrant further assessment
(Huggett et al. 2003). LogKOW values have been used as pre-
dictors for bioconcentration; however, this measurement was
originally developed for non-polar chemicals, and as a result
does not work for many chemicals (Schrieber et al. 2011).
The use of acute LC50 and QSAR in order to assess the
potential hazard of pharmaceuticals has been debated.
Although LC50 values are derived from experimental work,
they can be influenced by variables such as the number of
concentrations assessed (Hoyett et al. 2016). The primary con-
cern relating to pharmaceuticals in the environment is the
potential chronic exposure to low levels, and not acute toxic-
ity. As a result, they may affect endpoints which are not cov-
ered by traditional risk assessments (Johnson et al. 2017).
QSARs have been used to model the potential toxicity of
contaminants to fish, daphnia and algae. There are several
QSARmodels which have been proposed for use in predicting
ecotoxicity of pharmaceuticals which have found to vary in
accuracy (for example, de Roode et al. 2006; Sangion and
Gramatica 2016a).
There is evidence that fish are more sensitive than algae or
invertebrates as they retain many of the same drug targets as
humans (Donnachie et al. 2016). The FPM was developed in
order to utilise this information. A read-across approach can
be used in assessing the potential risk of pharmaceuticals to
invertebrates and algae. Fish share 86% of targets with
humans, 61% have been found to be conserved in daphnia
and 35% in algae (Gunnarsson et al. 2008). There is particular
concern surrounding the toxicity of antibiotics and statins to
algae, in part due to conserved pathways, but also due to the
inhibition of symbiotic bacteria (Guo et al. 2015). CEC result-
ed in a higher ranking for statins and two of the antibiotics
than LC50 values. Amoxicillin, on the other hand, was
highlighted by its acute toxicity and not by the FPM. Only
the RQ which included PECA exceeded 1 for amoxicillin,
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whereas this was exceeded by all of the FPM schemes. As a
result, the FPM and CEC will add a degree of protection for
organisms besides fish.
For many compounds, FPM and CECs resulted in similar
rankings. The minor influence PEC has on FPM confirms
what has been found in other comparisons between
prioritisation schemes (Roos et al. 2012). However,
ethinylestradiol, fluticasone propionate and beclomethasone
were highlighted by CECs, but not by FPMs as the PEC
values for these compounds were small. In this case,
ethinylestradiol had a low PEC; however, MECs were much
higher than this. Ethinylestradiol is a compound on the EU’s
priority watch list due to concern over its potential effects at
environmentally relevant concentrations. Johnson et al.
(2017) ranked chemicals based on their measured environ-
mental concentrations in UK rivers and measured ecotoxicity
concentrations, and found that ethinylestradiol was highlight-
ed as posing the greatest risk. As a result, it is important that
PEC results are accurate if FPM is going to be used. The use of
an assessment factor or ER value of 1000 allows for the most
conservative estimate of risk whilst accounting for uncertainty
in the PEC values.
Selecting a prioritisation scheme
It is important to consider the inclusion of compounds into a
scheme to begin with. Metoprolol, carbamazepine, aspirin and
sulfamethoxazole were four of the most cited pharmaceuticals
of concern in the prioritisation literature but were not in the 50
most prescribed compounds (Donnachie et al. 2016). The high
number of prescriptions does not necessarily translate into a
large mass of the compound; bronchodilators, for example,
were prescribed in high numbers, but at a very low mass. As
a result, certain compounds may be overlooked and it may be
necessary to select compounds based on their mass as well as
prescription numbers.
Of the PEC schemes used in this assessment, PECA is
the most suitable for assessing the relative exposure risk
as it requires limited data, but also conservatively esti-
mates the likelihood of pharmaceuticals entering the en-
vironment. It can be used to select pharmaceuticals for
which to further refine PECs based on local criteria be-
fore selection of compounds for monitoring in the envi-
ronment. Where information on the number of prescrip-
tions is not available, PECD is a better alternative as it
can work within the confines of available data.
Assessment of the potential effects of pharmaceuticals
should be used alongside PEC evaluations. LogKOW
offers a quick and easy method for assessing the relative
risk, based on potential bioaccumulation. The use of
CECs and FPM add an extra level of refinement, based
on utilising information on mammalian effects. FPM ap-
pears to give a conservative approach to prioritising
pharmaceuticals in comparison to acute RQs. As a result,
those compounds which also exceed the RQ threshold
should be of greater priority. The use of CECs over
FPMs allows the ranking of compounds independent of
PECs. However, both exposure risk and potential effects
should be included, as compounds found at small con-
centrations could still be enough to warrant an effect. For
example, ethinylestradiol was ranked as a low priority by
the PEC schemes, but inclusion of effect information
increased its ranking.
When prioritising pharmaceuticals, it is essential to take a
holistic approach which conservatively highlights potential
compounds of concern which warrant further assessment. It
is important to consider why the exercise is being carried out
and the question it is trying to address. There will not be a one
size fits all approach, and not all schemes will be appropriate
in all situations. As a result, the limitations to each of these
schemes need to be kept in mind.
Compounds of concern
The combination of PEC and effect criteria clearly high-
lights groups which should be a priority for further re-
search. Some assessments have only added one com-
pound from each class to the priority list, assuming that
each class will have a similar mode of action and sim-
ilar effect (Besse and Garric 2008). Antidepressants
were ranked high across all of the effect schemes, and
moderately for PECs too. Overall ranking between com-
pounds does not differ much; however, fluoxetine may
be of most of concern due to exceeding the RQ thresh-
old values when none of the others did. Fluoxetine is
commonly present on priority lists; however, some rank-
ings have pointed towards sertraline, citalopram and am-
itriptyline as representing a greater hazard (Besse and
Garric 2008; Roos et al. 2012; Sangion and Gramatica
2016b). Many of these antidepressants have been found
to have an effect on biota at environmentally relevant
concentrations and the use of FPM also highlights this
(Silva et al. 2015). To the authors’ knowledge, this is
the first prioritisation exercise which has highlighted
mirtazapine and venlafaxine to be a potential concern.
Similarly to antidepressants, candesartan and losartan
had moderate PEC rankings but high effect rankings for
FPM, CEC and LC50, whilst other anti-hypertensives had
a low ranking across both PEC and effect schemes. These
compounds are not commonly included in prioritisation
exercises; however, losartan has been present on priority
Fig. 4 Comparison of the relative ranking of compounds between effect
schemes: acute LC50, critical environmental concentrations, LOGKOW
and fish plasma model using PECA (FPMa), PECB (FPMb), PECc
(FPMc) and PECD (FPMd)
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lists previously (Besse and Garric 2008). Candesartan had
a higher ranking across schemes and as a result may be
more of a concern. The lipid regulators, atorvastatin and
simvastatin also had moderate to low PECs. However,
their high ranking among CECs and FPM means they
warrant further investigation.
Amoxicillin and flucloxacillin were two of four com-
pounds to exceed a RQ value of 1. Both of these compounds
were ranked highly as the result of PEC values. The effect
rankings of flucloxacillin were much higher than those of
amoxicillin. Flucloxacillin is not commonly present in moni-
toring or effects studies and there is still uncertainty about its
occurrence and impacts so it could be seen as a priority
compound.
Ibuprofen was ranked in the top 10 of all of schemes, with
the exception of acute LC50. Ibuprofen is the fifth most
prioritised compound in the prioritisation literature (Burns
et al. 2018b). The environmental impact of ibuprofen pollu-
tion has been the focus of many studies and its repeat presence
on priority lists and high rankings in the current study indicate
the importance in understanding its fate and effects.
Allopurinol may also warrant further assessment due to its
high exposure ranking and RQ value. Whilst it had a low
ranking for FPM, CEC and LogKOW values, it had an ER <
1000. Although Allopurinol has been stated to be a highly
prescribed drug in other EU countries (Küster and Adler
2014; Roos et al. 2012), Roos et al. (2012) carried out a com-
parison of first-tier prioritisation schemes, including FPM, on
582 pharmaceuticals in Sweden, and did not find it to be a
high priority. However, it has been highlighted on other prior-
ity lists based on exposure and effect criteria (Besse and Garric
2008; Linert et al. 2007). Despite this, it is not present in the
monitoring or ecotoxicity literature and it has only been mon-
itored in coastal waters in Spain, where it was not detected
(Rodrígues-Navas et al. 2013).
Other compounds such as metformin and gabapentin are
ranked in the top by PEC schemes, but inclusion of effect
criteria decreased their ranking. However, due their high
PECs, moderate effect rankings across FPM and acute LC50
values, they may still warrant further assessment. It is partic-
ularly important to understand their occurrence and fate.
Metformin in particular may be of concern as it now a widely
used drug, and its usage has increased rapidly over the last
decade (Oosterhuis et al. 2013).
This assessment also clearly highlights compounds
which are not of concern. Bronchodilators were ranked
in the bottom of all schemes and corticosteroids were
ranked at the bottom across all PEC schemes. This is
concurrent with other prioritisation exercises. As a result,
these compounds are not commonly featured in monitor-
ing campaigns or experimental effects work. Although
the priority ranking of corticosteroids increased with the
application of effect criteria, it was still low.
Future direction for the management
of pharmaceuticals in the environment
There is some evidence that EU policy has not used risk as-
sessment approaches to accurately identify compounds of
concern. In the present study, ibuprofen and naproxen had a
higher PEC and effect ranking than diclofenac even though
the latter has been placed on the EU priority watch list. This
could perhaps be attributed to the fall in diclofenac’s usage
over the past few years though (Mavragani et al. 2016).
Ethinylestradiol is another compound included on the EU pri-
ority watch list even though it had a low PEC ranking and
similar effect ranking; only CECs ranked it as a priority.
Similar results were seen in comparison of first-tier risk as-
sessments by Roos et al. (2012), where FPM did not result in a
high ranking for ethinylestradiol but CEC and three other
schemes did. As pharmaceuticals are designed to be biologi-
cally active, it is important that there is an understanding of
these pathways in non-target organisms in order to create bet-
ter risk assessments.
There has been an increasing interest in the occurrence of
pharmaceuticals in environmental compartments other than
effluent and water such as sediment and marine environments.
Comparatively, little is known about the occurrence of phar-
maceuticals in these areas (Fabbri and Franzellitti 2016; Gaw
et al. 2014) and use of the PEC schemes employed here may
not appropriately predict presence in these compartments.
Other properties, such as lipophilicity, pH and sediment type
may be more relevant in predicting the presence of pharma-
ceuticals in sediments, and in turn the potential risks to biota
which live within these systems (Al-Khazrajy and Boxall
2016). Salinity is also a defining factor of marine waters and
it is hypothesised that the physical-chemical characteristics of
some compounds may change in marine waters. For example,
the partition coefficient between sediment and water for es-
trone increases with increasing salinity, meaning concentra-
tions will be lower (Pal et al. 2010).
All pharmaceuticals are metabolised to a different degree,
yet only two prioritisation schemes have included metabolites
(Besse and Garric 2008; Capleton et al. 2006). If metabolism
and degradation play a significant role in the fate of pharma-
ceuticals then metabolites will be present in the environment.
Few studies have covered the occurrence and effects of me-
tabolites, many of which are inert, but some of which have
been found to be pharmacologically active and even toxic
(García-Cambero et al. 2015).
Conclusion
Prioritisation schemes should include assessments of the po-
tential of a compound to enter the environment as well its
potential toxicity. Excretion of pharmaceuticals had a large
3488 Environ Sci Pollut Res (2019) 26:3479–3491
influence on the ranking of PECs for different compounds,
and as a result should be included in these calculations.
CECs should be used alongside PECs in order to assess po-
tential hazard; both of these schemes result in a conservative
estimate of risk, and highlight compounds which warrant fur-
ther assessment. Antidepressants, statins, antibiotics,
candesartan, losartan and ibuprofen were highlighted as the
substances of greatest environmental concern.
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